-

Invenra Inc. Announces a Strategic Research Agreement with Astellas Pharma in Therapeutic Bispecific Antibody Discovery

MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic research agreement with Astellas Pharma, a global pharmaceutical company with a vision to turn innovative science into value for patients. This agreement will leverage Invenra’s cutting-edge B-Body® bispecific antibody platform to support Astellas’ focused research and development initiatives.

Under the agreement, Astellas will have access to Invenra’s B-Body technology, marking a thoughtful step toward advancing their bispecific therapeutic research. At the conclusion of the research, Astellas will have the option to negotiate future licenses.

Dr. Roland Green, CEO of Invenra, remarks, “We are honored to partner with the Astellas team, one of the world’s foremost developers of therapeutics. We are excited by the potential of this partnership to yield profound benefits to patients in need.”

Both companies share a commitment to advancing healthcare through dedicated scientific research, aiming to bring effective and innovative treatments to patients globally.

About Invenra Inc:

Driven by our mission to deliver groundbreaking therapies to patients worldwide and a commitment to innovation and excellence, Invenra is a leading bispecific antibody technology company. Our proprietary B-Body® platform offers profound advantages in discovery, manufacturing, and formulation, along with true "Plug & Play" performance, enabling rapid engineering of therapeutics. Our extensive portfolio of wholly owned and partnered molecules includes first and best-in-class bispecifics, making us a pioneer in therapeutic innovation.

Contacts

Invenra Media Contact
Bryan Glaser
Senior Vice President Business Development
Invenra Inc.
608-441-8319
bglaser@invenra.com

Invenra Inc.


Release Versions

Contacts

Invenra Media Contact
Bryan Glaser
Senior Vice President Business Development
Invenra Inc.
608-441-8319
bglaser@invenra.com

More News From Invenra Inc.

Invenra Launches “52 Views of Cancer” Art Deck at World ADC Conference

MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc., a biotechnology company developing multispecific antibody therapeutics, announced the launch of its first 52 Views of Cancer, a playing card deck showcasing original artwork by people affected by cancer. Invenra is debuting the deck at the World ADC Conference in San Diego.The project links cancer journeys directly to researchers, clinicians, and drug developers. The launch also marks the company’s expansion into antibody-drug conjugate (ADC) asset d...

Invenra Accelerates Commercial Strategy with Appointment of Chief Commercial Officer

MADISON, Wis.--(BUSINESS WIRE)--Invenra, Inc., a biotechnology company pioneering multispecific antibody therapeutics, today announced the appointment of Nancy J. Sandy as Chief Commercial Officer. The hire marks a significant step in the Invenra strategy to bring its expanding platform portfolio, including its B-Body® bispecific and newly launched T-Body™ trispecific antibody platforms, to pharmaceutical and biotech partners worldwide. Invenra enters this next chapter with strong momentum. The...

Invenra To Feature Cancer Patient Art in Upcoming Antibody Therapy Development Project

MADISON, Wis.--(BUSINESS WIRE)--Invenra, Inc., a biotechnology company pioneering multispecific antibody therapeutics, is requesting cancer patient and survivor artwork, which will be featured in an innovative project linking patient experiences to people doing important cancer research and development. If selected, artists will earn a $1,000 stipend and have their work featured in a one-of-a-kind playing card deck that celebrates the creativity, resilience, and spirit of people whose lives hav...
Back to Newsroom